Lexicon Pharmaceuticals FDA Advisory Committee Meeting For Zynquista, Scheduled For October 31, 2024
Portfolio Pulse from Benzinga Newsdesk
Lexicon Pharmaceuticals announced that the FDA will hold an advisory committee meeting on October 31, 2024, to discuss the approval of Zynquista for use in adults with type 1 diabetes and chronic kidney disease. The PDUFA goal date is set for December 20, 2024.
August 21, 2024 | 12:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Lexicon Pharmaceuticals is set for an FDA advisory committee meeting on October 31, 2024, for its drug Zynquista, aimed at treating type 1 diabetes and CKD. The PDUFA date is December 20, 2024.
The FDA advisory committee meeting is a critical step in the approval process for Zynquista, which could significantly impact Lexicon's market position if approved. The unchanged PDUFA date suggests a clear timeline for potential approval, which is positive for the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100